{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:47:22Z","timestamp":1794469642254,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ygyno.2023.05.060","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T15:43:41Z","timestamp":1685461421000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial"],"prefix":"10.1016","volume":"175","author":[{"given":"John Devin","family":"Peipert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Goble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Isaacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.05.060_bb0005","series-title":"Global Cancer Observatory: Cancer Today","author":"International Agency for Research on Cancer","year":"2023"},{"issue":"27","key":"10.1016\/j.ygyno.2023.05.060_bb0010","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1200\/JCO.19.00314","article-title":"Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer","volume":"37","author":"Bouberhan","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.05.060_bb0015","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/annonc\/mdy174","article-title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","volume":"29","author":"Mirza","year":"2018","journal-title":"Ann. Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2023.05.060_bb0020","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian Cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10106","key":"10.1016\/j.ygyno.2023.05.060_bb0025","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet."},{"issue":"30","key":"10.1016\/j.ygyno.2023.05.060_bb0030","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1200\/JCO.19.03107","article-title":"Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of Rucaparib maintenance treatment in patients with recurrent ovarian carcinoma","volume":"38","author":"Oza","year":"2020","journal-title":"J. Clin. Oncol.: Off. J. American Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.060_bb0035","series-title":"Core Patient-Reported Outcomes in Cancer Clinical Trials Guidance for Industry","author":"United States Food and Drug Administration","year":"2021"},{"issue":"5","key":"10.1016\/j.ygyno.2023.05.060_bb0040","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","article-title":"Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Ledermann","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.05.060_bb0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2014.12.002","article-title":"Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18)","volume":"136","author":"Jensen","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.05.060_bb0050","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2010.09.025","article-title":"A new index of priority symptoms in advanced ovarian cancer","volume":"120","author":"Jensen","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.05.060_bb0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-018-4713-2","volume":"169","author":"Wagner","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2023.05.060_bb0060","doi-asserted-by":"crossref","first-page":"e19136","DOI":"10.1200\/JCO.2020.38.15_suppl.e19136","article-title":"Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients","volume":"38","author":"Peipert","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.05.060_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2020.05.045","article-title":"The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: a post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma","volume":"159","author":"Colombo","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2023.05.060_bb0070","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2023.05.060_bb0075","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian Cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.05.060_bb0080","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11136-019-02367-7","article-title":"Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review","volume":"29","author":"Charton","year":"2020","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ygyno.2023.05.060_bb0085","series-title":"Broadening the Definition of Tolerability in Cancer Clinical Trials to Capture the Patient Experience","author":"Basch","year":"2020"},{"issue":"11","key":"10.1016\/j.ygyno.2023.05.060_bb0090","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.05.060_bb0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.05.060_bb0100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2021.08.005","article-title":"Health-related quality of life at the SPARTAN final analysis of Apalutamide for nonmetastatic castration-resistant prostate Cancer patients receiving androgen deprivation therapy","volume":"8","author":"Oudard","year":"2021","journal-title":"Eur. Urol. Focus."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2023.05.060_bb0105","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1200\/JCO.2021.39.15_suppl.9057","article-title":"Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC)","volume":"39","author":"Spira","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.05.060_bb0110","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11523-020-00715-z","article-title":"Management of Adverse Events during Rucaparib Treatment for relapsed ovarian Cancer: a review of published studies and practical guidance","volume":"15","author":"Lorusso","year":"2020","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ygyno.2023.05.060_bb0115","article-title":"Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting","volume":"12","author":"Tookman","year":"2020","journal-title":"Therapeut. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.05.060_bb0120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1037\/0022-006X.59.1.12","article-title":"Clinical significance: A statistical approach to defining meaningful change in psychotherapy research","volume":"59","author":"Jacobson","year":"1991","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"5","key":"10.1016\/j.ygyno.2023.05.060_bb0125","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s11136-022-03200-4","article-title":"Likely change indexes improve estimates of individual change on patient-reported outcomes","volume":"32","author":"Peipert","year":"2023","journal-title":"Qual Life Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823003013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:52:53Z","timestamp":1715820773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823003013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":25,"alternative-id":["S0090825823003013"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.05.060","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.05.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}